Headquartered in Fengxian District, Shanghai, Shanghai Minbiotech Co., Ltd. specializes in the research, development, and production of high-grade pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for the biopharmaceutical industry. The company operates a research and development center spanning over 2,000 square meters and a production facility covering more than 53333 square meters . In addition to supplying products, the company offers services such as technology development, technology transfer, and technical exchanges, with the aim of providing comprehensive supply and solutions to clients in the biopharmaceutical industry.
The company is dedicated to the R&D and production of biopharmaceuticals. Its flagship products include monoclonal antibodies, ADC small-molecule toxins, active pharmaceutical ingredients (APIs) for COVID-19 treatments, nucleosides required for mRNA vaccine production, as well as a variety of high-end generic and innovative drugs. Throughout its rapid growth, the company has consistently adhered to the management philosophy of “ Integrity, Professionalism, and Innovation, ” upholding a quality- and market-oriented approach. It strives to win market share through its brand and collaborates with domestic and international clients through professional services!
Allow me to provide a brief overview of our company's most popular products: Semaglutide, Tirzepatide, Retatrutide, Oglitrelone, Dydrogesterone, Oseltamivir Phosphate, Fidaxomicin, Dabaivancin Hydrochloride, various ADC payloads, and monoclonal antibodies.
CN
